Mutations in the hepatocyte nuclear factor-1a (HNF1a) gene and HNF-4a gene cause maturity onset diabetes of the young (MODY)-3 [1] and MODY1 [2] , respectively. Hepatocyte nuclear factor-1a belongs to a family of homeodomain-containing transcription factors and its expression is regulated by . Clinical studies have shown MODY1 and MODY3 are caused predominantly by insulin secretory failure [4, 5] . When insulin secretion was examined in stepped glucose infusion studies [4, 5] , non-diabetic MODY1 and MODY3 mutation carriers showed reduced insulin secretory responses to glucose. Conversely, another report showed that in a non-diabetic carrier of the MODY3 mutation, the insulin secreto- Diabetologia (1999) 
1a288 t) was overexpressed in hepatoma cells (HepG2) and murine insulinoma cells (MIN6) using a recombinant adenovirus system and expression of the HNF-1a target genes and insulin secretion were examined. Results. Expression of phenylalanine hydroxylase and a1-antitrypsin genes, the target genes of HNF1a, was suppressed in HepG2 cells by overexpression of HNF-1a288 t. In MIN6 cells, overexpression of HNF-1a288 t did not change insulin secretion stimulated by glucose (5 mmol/l and 25 mmol/l) or leucine (20 mmol/l). Potentiation of insulin secretion by arginine (20 mmol/l, in the presence of 5 mmol/l or 25 mmol/l glucose) was, however, reduced (p < 0.0001 and p = 0.027, respectively). Similarly reduced responses were observed when stimulated with homoarginine. Expression of the cationic amino acid transporter-2 was not reduced and insulin secretory response to membrane depolarization by 50 mmol/l KCl was intact. Conclusion/interpretation. The HNF-1a288 t, which is structurally similar to the mutant HNF-1a expressed from the common MODY3 allele, P291fsinsC, exerts a dominant negative effect. Suppression of HNF-1a in MIN6 cells severely impaired potentiation of insulin secretion by arginine, whereas glucose-stimulated and leucine-stimulated insulin secretion was intact. Our findings delineate the complex nature of betacell failure in patients with MODY3. This cell model will be useful for further investigation of the mechanism of insulin secretory defects in these patients.
[Diabetologia (1999) 42: 887±891] Keywords MODY, hepatocyte nuclear factor-1a, recombinant adenovirus, MIN6 cells, dominant negative effect, arginine. ry response to an intravenous glucose load was not impaired, but exaggerated [6] . It is also reported that in a non-diabetic MODY1 mutation carrier, insulin secretion in response to sustained hyperglycaemia (11.1 mmol/l) or bolus glucose infusion was intact [7] . These observations suggest that glucose-stimulated insulin secretion is not impaired in certain conditions in the carriers of MODY1 and MODY3 mutations. The mechanism underlying this apparent discrepancy has not been explained.
One common MODY3 mutation of the HNF-1a gene, P291fsinsC, apparently results in the expression of a truncated protein, which retains the dimerization and the DNA binding domains, but lacks the transcriptional activation domain. This mutant protein is likely to exert dominant negative effects on target gene transcriptional activation, since the mutant protein dimerizes with intact HNF-1a, or another related partner HNF-1b, producing a transactivationally inactive heterodimer [8] . Here, to produce a culture cell model and study the molecular mechanism of insulin secretory defects in HNF-1a deficient MODY3 beta cells, we constructed a recombinant adenovirus and efficiently expressed a mutant HNF-1a, HNF1a288 t, which was structurally similar to that expressed from the P291fsinsC MODY3 mutant allele, in culture cells. The effect of HNF-1a288 t overexpression on target gene transcription and insulin secretion were studied using this model.
Materials and methods
Plasmid construction. Mouse HNF-1a cDNA (Genbank accession no. M57 966) and mouse cationic amino acid transporter-2 (mCAT2) cDNA [9] were obtained from MIN6 cells by reverse transcription (RT)-PCR. The mouse HNF-1a expression plasmid (pcDNA-mHNF-1a) was constructed by cloning a coding region of mouse HNF-1a cDNA into pcDNA3 (Invitrogen, Carlsbad Calif., USA). The expression plasmid for the truncated HNF-1a (pcDNA-mHNF-1a288 t) was constructed by cloning a partial cDNA fragment with a termination codon after the 288th codon.
The reporter plasmid (pGL3-TK-bfib3) was designed to have three copies of HNF-1a binding sites (TGTCAAATAT-TAACTAAAGGG) in tandem in front of the herpes simplex virus thymidine kinase promoter, followed by the firefly luciferase gene.
Reporter assay. To HeLa cells, pcDNA-mHNF-1a or pcDNAmHNF-1a288 t was cotransfected with pGL3-TK-bfib3 and pCMVb (Clontech, Palo Alto, Calif., USA) by the lipofection method using TransIT-LT1 (PanVera Corporation, Madison, Wis., USA) according to the supplier's protocols. Luciferase assay was carried out 48 h after transfection. Luciferase activity was normalized for transfection efficiency based on b-galactosidase activity.
Adenovirus mediated gene transduction. Recombinant adenoviruses AdexlCAmHNF-1a288 t and AdexlCAlacZ, encoding Escherichia coli b-galactosidase, was constructed as described previously [10] . Adenovirus infection was done as described in [11] at a multiplicity of infection (MOI) of 10±20 pfu/cell, unless otherwise specified.
Semiquantification of a1-antitrypsin and phenylalanine hydroxylase mRNA. We extracted RNA from HepG2 cells 3 days after viral infection. The RT-PCR was carried out using specific primer sets (5 ¢-GAA GAA GTT GGT GCA TTG GC-3 ¢ + 5 ¢-TTG GAT GGC TGT CTT CTC C-3 ¢ for phenylalanine hydroxylase (PAH), 5 ¢-AAT GCC GTC TTC TGT CTC G-3 ¢ + 5 ¢-CGC TCT TCA GAT CAT AGG TTC C-3 ¢ for a1-antitrypsin (a1-AT), and 5 ¢-ATG TGC AAG GCC GGC TTC GCG GGC GAC G-3 ¢ + 5 ¢-CAG CCA GGT CCA GAC GCA GGA TGG CAT G-3 ¢ for b-actin) in the presence of [a-32 P] dCTP. Equal aliquots of PCR products were electrophoresed through non-denaturing 5 % polyacrylamide gel. Radioactivities of the specific products were quantified using a BAS 2000 phosphor imager (Fuji Film, Tokyo, Japan).
Insulin release assay. Insulin secretion from MIN6 cells was measured by the static incubation method. After preincubation for 30 min in HEPES-balanced Krebs-Ringer bicarbonate buffer supplemented with 0.5 % bovine serum albumin (KRB-HB) and 5 mmol/l glucose, the media were replaced with KRB-HB containing various secretagogues. After a further 2 h incubation at 37°C, media were collected and immunoreactive insulin was measured by RIA using rat insulin as a standard. The amounts of insulin secreted were corrected by the amounts of cell protein in each well.
Statistical analysis. Data are presented as means ± SEM. The statistical significance of differences between mean values was assessed using the unpaired-Student's t test, or Mann Whitney's U-test whenever appropriate. P-values less than 0.05 were considered significant.
Results
Truncated HNF-1a exerts a dominant negative effect on target gene expression. The HNF-1a288 t was defective in promoter activation. When pcDNAmHNF-1a was cotransfected with pGL3-TK-bfib3, luciferase activity increased 6.9 ± 1.9 fold. In contrast, pcDNA-mHNF-1a288 t increased luciferase activity only 1.3 ± 0.2 fold.
With the recombinant adenovirus AdexlCA-HNF-1a288 t, the mutant HNF-1a was efficiently overexpressed in culture cells when examined by western blot analysis (data not shown). We then examined the effect on target gene expression in HepG2 cells. After 3 days of infection with Adexl-CA-HNF-1a288 t at MOI of 30, expression of the PAH and a1-AT genes, which is largely dependent on HNF-1a in hepatocytes [12] , was suppressed to 10 and 25 % of controls, respectively (Fig. 1 ). In contrast, under this condition, the expression of b-actin was not changed. Thus, overexpression of HNF1a288 t suppressed expression of PAH and a1-AT genes, via a dominant negative effect on intrinsic HNF-1a.
Expression of dominant negative HNF-1a impairs arginine induced insulin secretion from MIN6 cells. We then overexpressed HNF-1a288 t in MIN6 cells. As shown in Fig. 2 , at 5 mmol/l glucose, insulin secretion from MIN6 cells overexpressing truncated HNF-1a (MIN6±288 t) (105.5 ± 12.2 ng/ng protein) did not differ from that from MIN6 cells overexpressing b-galactosidase (MIN6-lacZ) (112.0 ± 11.2 ng/ng protein) (p = 0.215). Insulin secretion at 25 mmol/l glucose was increased by 11.8 ± 1.0 fold (MIN6± 288 t) and 9.4 ± 0.7 fold (MIN6-lacZ) compared with that of MIN6-lacZ at 5 mmol/l glucose, without significant difference (p = 0.060). In the presence of 5 mmol/l glucose l-leucine (20 mmol/l) also increased insulin secretion to the same extent in both cells (p = 0.505).
In contrast to the responses to glucose and leucine, potentiation of insulin secretion by l-arginine was severely impaired. In the presence of 5 mmol/l glucose, 20 mmol/l l-arginine potentiated insulin secretion from MIN6-lacZ cells (8.08 ± 0.50 fold). This potentiation was, however, nearly abolished in MIN6±288 t cells. Similarly, diminished potentiation of insulin secretion was observed for arginine at 25 mmol/l glucose and for homoarginine, a non-metabolizable arginine analogue. One of the mechanisms by which arginine potentiates insulin secretion is direct depolarization of the beta-cell membrane potential through uptake of cationic amino acids into cells [13] . Thus, we examined the insulin secretory response to membrane depolarization by 50 mmol/l KCl, but found no statistically significant difference.
To exclude the possibility that the impairment of arginine potentiation of insulin secretion is due to adenovirus infection, we repeated the experiments at various MOIs. Potentiation of insulin secretion by arginine was severely impaired in cells infected with Ade 1CA-HNF-1a288 t even at a MOI of 1.6, whereas it was not altered in cells infected with Ade 1CA-lacZ even at a MOI as high as 36 (data not shown).
Expression of insulin, GLUT2 and cationic amino acid transporter mRNA in MIN6 cells expressing dominant negative HNF-1a. It has been suggested that HNF-1a affects the expression of insulin and GLUT2 genes [14, 15] , but no differences in their mRNA expression was observed between MIN6±288 t and MIN6-lacZ cells (Fig. 3 and data not  shown) . The cationic amino acid transporter CAT2 was suggested to be involved in the potentiation of insulin secretion by arginine [13] . No reduction in CAT2 mRNA was, however, observed in MIN6±288 t cells (Fig. 3) .
Discussion
We first showed that overexpression of the truncated HNF-1a, HNF-1a288 t, suppressed target gene (PAH and a1-AT) expression in hepatoma cells. This effect is attributable to a dominant negative effect of the mutant HNF-1a on the intrinsic HNF-1a. We then studied the effects of decreased HNF-1a function on insulin secretion.
In MIN6±288 t, impairment of arginine-stimulated insulin secretion was striking. Potentiation of insulin secretion by arginine was barely detectable at either the basal (5 mmol/l) or a high (25 mmol/l) glucose concentration. Arginine is a potent potentiator of insulin secretion in the presence of glucose, although the mechanism is still not clear. Nitric oxide, which is generated from arginine, was proposed as a mediator of insulin secretion [16] but this is controversial [13, 17] . A more favoured hypothesis is that the uptake of cationic amino acids directly depolarizes the beta-cell membrane and triggers insulin secretion [13, 18] . Recently, the high capacity, low affinity cationic amino acid transporter, CAT2 was suggested to mediate the potentiation of insulin secretion [13] . The expression of CAT2 mRNA in MIN6±288 t cells was, however, not decreased, but increased compared with MIN6-lacZ cells (Fig. 3) . Thus, impaired potentiation is not simply explained by decreased arginine transport by CAT2. Insulin secretion evoked by direct membrane depolarization by 50 mmol/l KCl was not impaired in MIN6±288 t cells (Fig. 2) , suggesting that the insulin secretory pathway was intact after depolarization of this membrane. These results indicate that undefined mechanisms other than direct membrane depolarization may account for the potentiation of insulin secretion by arginine, and the pathway is likely to be impaired in MIN6±288 t cells.
In MIN6±288 t cells, glucose-stimulated insulin secretion was not impaired under our experimental conditions, in which the glucose concentration was changed rapidly and sustained for 2 h. Leucine, which stimulates insulin secretion through intracellular metabolism and ATP generation, also stimulated insulin secretion to the same extent as control MIN6-lacZ cells. The results indicate that the basic machinery necessary for glucose-stimulated insulin secretion is intact. Our results were unexpected given those of earlier clinical studies [5] and pancreas perfusion and perifusion studies of islets from diabetic HNF1a (±/±) mice [19] . Insulin secretory defects in human MODY3 patients seems not to be simple. Although insulin secretion was impaired in some patients with MODY3 [5] , another report described a non-diabetic carrier of a MODY3 mutation, in whom the insulin response to an intravenous glucose load was somewhat exaggerated, despite the response to an oral glucose load being lower than in controls [6] . It is also noteworthy that in a non-diabetic MODY1 mutation carrier, insulin secretion in response to sustained hyperglycaemia (11.1 mmol/l) or bolus glucose infusion was not impaired [7] . Because the expression of HNF-1a is regulated by HNF-4a [3] , mechanisms of beta-cell failure in MODY1 patients probably overlap those of MODY3 patients. These findings indicate that in certain circumstances, glucose-stimulated insulin secretion is intact in beta cells of MODY1/3 patients as in MIN6±288 t cells under our experimental conditions. Insulin secretion from the islets of HNF-1a ( ± ) mice was normal [19] . In the MIN6±288 t cells, transcriptional activity of HNF-1a is likely to be suppressed by overexpression of the dominant negative mutant HNF-1a. One possible explanation for the normal glucose-stimulated insulin secretion in HNF-1a ( ± ) mouse islets and MIN6±288 t cells is that in murine beta cells, glucosestimulated insulin secretion is less sensitive to the decreased HNF-1a activity than in human beta cells. A changed expression pattern of the transcription regulators in the MIN6 insulinoma cells could also be the factor. It is also possible that the insulin secretory response from HNF-1a deficient beta cells remains relatively intact when there is a rapid increase in glucose concentration, or prolonged exposure to a high glucose concentration as under our experimental conditions (2 h at 25 mmol/l) but is impaired in response to a gradual increase in glucose concentration.
Clearly, the molecular mechanisms of beta-cell dysfunction in the MODY3 patients are complex. As a transcription factor, HNF-1a, regulates expression of the multiple genes in beta cells. Although the target genes are still not well defined, they are probably involved in multiple steps from secretagogue stimulation to insulin secretion and also possibly in insulin biosynthesis. The expression of two possible target genes, the GLUT2 and the insulin genes, was not impaired in MIN6±288 t cells (Fig. 3 and data not shown) and HNF-1a (±/±) mice [19] and thus their expression is probably less dependent on HNF-1a in beta cells. Insulin secretion from MIN6±288 t cells is clearly abnormal in respect to arginine potentiation. Insulin secretory response to arginine was also diminished in non-diabetic MODY1 subjects with a mutation in the HNF-4a gene [7] and in HNF-1a (±/±) mouse islets [19] . Therefore, MIN6±288 t cells could represent at least a part of the beta cells in MODY3 patients. The molecular mechanism whereby the suppressed HNF-1a function leads to insulin secretory defects observed in MIN6±288 t cells and in beta cells from MODY3 patients, is not fully understood. Elucidating the mechanisms underlying these unique insulin secretory defects and their link to the MODY3 phenotype would facilitate further understanding of the regulation and maintenance of normal beta-cell function. It may lead to the discovery of another key element in the regulation of beta-cell function, abnormalities of which play a role in the more common form of type 2 diabetes mellitus.
